Report Thumbnail
Product Code LP09140124862SC
Published Date 2024/4/15
English133 PagesGlobal

Global Bacterial Vaccines for Humans Market Growth 2024-2030Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code LP09140124862SC◆The Apr 2026 edition is also likely available. We will check with the publisher immediately.
Published Date 2024/4/15
English 133 PagesGlobal

Global Bacterial Vaccines for Humans Market Growth 2024-2030Pharmaceutical_LifeSciense Market



Abstract


Summary

A bacterial vaccine is a type of vaccine used to prevent infections caused by bacteria. This type of vaccine works by stimulating the immune system to produce an immune response to a specific bacterium, thereby increasing the body's resistance to that bacterium. Bacterial vaccines usually contain killed or weakened bacteria, their isolated antigens, or their synthesized proteins.
The global Bacterial Vaccines for Humans market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Bacterial Vaccines for Humans Industry Forecast” looks at past sales and reviews total world Bacterial Vaccines for Humans sales in 2023, providing a comprehensive analysis by region and market sector of projected Bacterial Vaccines for Humans sales for 2024 through 2030. With Bacterial Vaccines for Humans sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bacterial Vaccines for Humans industry.
This Insight Report provides a comprehensive analysis of the global Bacterial Vaccines for Humans landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bacterial Vaccines for Humans portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Bacterial Vaccines for Humans market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bacterial Vaccines for Humans and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bacterial Vaccines for Humans.
United States market for Bacterial Vaccines for Humans is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Bacterial Vaccines for Humans is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Bacterial Vaccines for Humans is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Bacterial Vaccines for Humans players cover Merck, Sanofi, GSK, Mitsubishi Tanabe Pharma and Pfizer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Bacterial Vaccines for Humans market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
Meningococcal Vaccine
Hib Vaccine
BCG Vaccine
Typhoid Vaccine
Anthrax Vaccine
Segmentation by application
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck
Sanofi
GSK
Mitsubishi Tanabe Pharma
Pfizer
Bayer
Emergent BioSolutions
Walvax
Chengdu Kanghua Biological Products Co., Ltd.
Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd.
Zhejiang Tianyuan Biopharmaceutical Co., Ltd.
Beijing Institute of Biological Products Co., Ltd.
CanSino Biological Co., Ltd.
Hualan Biological Vaccine Co., Ltd.
Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd.
Key Questions Addressed in this Report
What is the 10-year outlook for the global Bacterial Vaccines for Humans market?
What factors are driving Bacterial Vaccines for Humans market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Bacterial Vaccines for Humans market opportunities vary by end market size?
How does Bacterial Vaccines for Humans break out type, application?

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats
  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global Bacterial Vaccines for Humans Annual Sales 2019-2030
      • 2.1.2 World Current & Future Analysis for Bacterial Vaccines for Humans by Geographic Region, 2019, 2023 & 2030
      • 2.1.3 World Current & Future Analysis for Bacterial Vaccines for Humans by Country/Region, 2019, 2023 & 2030
    • 2.2 Bacterial Vaccines for Humans Segment by Type
      • 2.2.1 Meningococcal Vaccine
      • 2.2.2 Hib Vaccine
      • 2.2.3 BCG Vaccine
      • 2.2.4 Typhoid Vaccine
      • 2.2.5 Anthrax Vaccine
    • 2.3 Bacterial Vaccines for Humans Sales by Type
      • 2.3.1 Global Bacterial Vaccines for Humans Sales Market Share by Type (2019-2024)
      • 2.3.2 Global Bacterial Vaccines for Humans Revenue and Market Share by Type (2019-2024)
      • 2.3.3 Global Bacterial Vaccines for Humans Sale Price by Type (2019-2024)
    • 2.4 Bacterial Vaccines for Humans Segment by Application
      • 2.4.1 Hospital
      • 2.4.2 Clinic
      • 2.4.3 Others
    • 2.5 Bacterial Vaccines for Humans Sales by Application
      • 2.5.1 Global Bacterial Vaccines for Humans Sale Market Share by Application (2019-2024)
      • 2.5.2 Global Bacterial Vaccines for Humans Revenue and Market Share by Application (2019-2024)
      • 2.5.3 Global Bacterial Vaccines for Humans Sale Price by Application (2019-2024)
  • 3 Global Bacterial Vaccines for Humans by Company

    • 3.1 Global Bacterial Vaccines for Humans Breakdown Data by Company
      • 3.1.1 Global Bacterial Vaccines for Humans Annual Sales by Company (2019-2024)
      • 3.1.2 Global Bacterial Vaccines for Humans Sales Market Share by Company (2019-2024)
    • 3.2 Global Bacterial Vaccines for Humans Annual Revenue by Company (2019-2024)
      • 3.2.1 Global Bacterial Vaccines for Humans Revenue by Company (2019-2024)
      • 3.2.2 Global Bacterial Vaccines for Humans Revenue Market Share by Company (2019-2024)
    • 3.3 Global Bacterial Vaccines for Humans Sale Price by Company
    • 3.4 Key Manufacturers Bacterial Vaccines for Humans Producing Area Distribution, Sales Area, Product Type
      • 3.4.1 Key Manufacturers Bacterial Vaccines for Humans Product Location Distribution
      • 3.4.2 Players Bacterial Vaccines for Humans Products Offered
    • 3.5 Market Concentration Rate Analysis
      • 3.5.1 Competition Landscape Analysis
      • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
    • 3.6 New Products and Potential Entrants
    • 3.7 Mergers & Acquisitions, Expansion
  • 4 World Historic Review for Bacterial Vaccines for Humans by Geographic Region

    • 4.1 World Historic Bacterial Vaccines for Humans Market Size by Geographic Region (2019-2024)
      • 4.1.1 Global Bacterial Vaccines for Humans Annual Sales by Geographic Region (2019-2024)
      • 4.1.2 Global Bacterial Vaccines for Humans Annual Revenue by Geographic Region (2019-2024)
    • 4.2 World Historic Bacterial Vaccines for Humans Market Size by Country/Region (2019-2024)
      • 4.2.1 Global Bacterial Vaccines for Humans Annual Sales by Country/Region (2019-2024)
      • 4.2.2 Global Bacterial Vaccines for Humans Annual Revenue by Country/Region (2019-2024)
    • 4.3 Americas Bacterial Vaccines for Humans Sales Growth
    • 4.4 APAC Bacterial Vaccines for Humans Sales Growth
    • 4.5 Europe Bacterial Vaccines for Humans Sales Growth
    • 4.6 Middle East & Africa Bacterial Vaccines for Humans Sales Growth
  • 5 Americas

    • 5.1 Americas Bacterial Vaccines for Humans Sales by Country
      • 5.1.1 Americas Bacterial Vaccines for Humans Sales by Country (2019-2024)
      • 5.1.2 Americas Bacterial Vaccines for Humans Revenue by Country (2019-2024)
    • 5.2 Americas Bacterial Vaccines for Humans Sales by Type
    • 5.3 Americas Bacterial Vaccines for Humans Sales by Application
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil
  • 6 APAC

    • 6.1 APAC Bacterial Vaccines for Humans Sales by Region
      • 6.1.1 APAC Bacterial Vaccines for Humans Sales by Region (2019-2024)
      • 6.1.2 APAC Bacterial Vaccines for Humans Revenue by Region (2019-2024)
    • 6.2 APAC Bacterial Vaccines for Humans Sales by Type
    • 6.3 APAC Bacterial Vaccines for Humans Sales by Application
    • 6.4 China
    • 6.5 Japan
    • 6.6 South Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia
    • 6.10 China Taiwan
  • 7 Europe

    • 7.1 Europe Bacterial Vaccines for Humans by Country
      • 7.1.1 Europe Bacterial Vaccines for Humans Sales by Country (2019-2024)
      • 7.1.2 Europe Bacterial Vaccines for Humans Revenue by Country (2019-2024)
    • 7.2 Europe Bacterial Vaccines for Humans Sales by Type
    • 7.3 Europe Bacterial Vaccines for Humans Sales by Application
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia
  • 8 Middle East & Africa

    • 8.1 Middle East & Africa Bacterial Vaccines for Humans by Country
      • 8.1.1 Middle East & Africa Bacterial Vaccines for Humans Sales by Country (2019-2024)
      • 8.1.2 Middle East & Africa Bacterial Vaccines for Humans Revenue by Country (2019-2024)
    • 8.2 Middle East & Africa Bacterial Vaccines for Humans Sales by Type
    • 8.3 Middle East & Africa Bacterial Vaccines for Humans Sales by Application
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends
  • 10 Manufacturing Cost Structure Analysis

    • 10.1 Raw Material and Suppliers
    • 10.2 Manufacturing Cost Structure Analysis of Bacterial Vaccines for Humans
    • 10.3 Manufacturing Process Analysis of Bacterial Vaccines for Humans
    • 10.4 Industry Chain Structure of Bacterial Vaccines for Humans
  • 11 Marketing, Distributors and Customer

    • 11.1 Sales Channel
      • 11.1.1 Direct Channels
      • 11.1.2 Indirect Channels
    • 11.2 Bacterial Vaccines for Humans Distributors
    • 11.3 Bacterial Vaccines for Humans Customer
  • 12 World Forecast Review for Bacterial Vaccines for Humans by Geographic Region

    • 12.1 Global Bacterial Vaccines for Humans Market Size Forecast by Region
      • 12.1.1 Global Bacterial Vaccines for Humans Forecast by Region (2025-2030)
      • 12.1.2 Global Bacterial Vaccines for Humans Annual Revenue Forecast by Region (2025-2030)
    • 12.2 Americas Forecast by Country
    • 12.3 APAC Forecast by Region
    • 12.4 Europe Forecast by Country
    • 12.5 Middle East & Africa Forecast by Country
    • 12.6 Global Bacterial Vaccines for Humans Forecast by Type
    • 12.7 Global Bacterial Vaccines for Humans Forecast by Application
  • 13 Key Players Analysis

    • 13.1 Merck
      • 13.1.1 Merck Company Information
      • 13.1.2 Merck Bacterial Vaccines for Humans Product Portfolios and Specifications
      • 13.1.3 Merck Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
      • 13.1.4 Merck Main Business Overview
      • 13.1.5 Merck Latest Developments
    • 13.2 Sanofi
      • 13.2.1 Sanofi Company Information
      • 13.2.2 Sanofi Bacterial Vaccines for Humans Product Portfolios and Specifications
      • 13.2.3 Sanofi Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
      • 13.2.4 Sanofi Main Business Overview
      • 13.2.5 Sanofi Latest Developments
    • 13.3 GSK
      • 13.3.1 GSK Company Information
      • 13.3.2 GSK Bacterial Vaccines for Humans Product Portfolios and Specifications
      • 13.3.3 GSK Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
      • 13.3.4 GSK Main Business Overview
      • 13.3.5 GSK Latest Developments
    • 13.4 Mitsubishi Tanabe Pharma
      • 13.4.1 Mitsubishi Tanabe Pharma Company Information
      • 13.4.2 Mitsubishi Tanabe Pharma Bacterial Vaccines for Humans Product Portfolios and Specifications
      • 13.4.3 Mitsubishi Tanabe Pharma Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
      • 13.4.4 Mitsubishi Tanabe Pharma Main Business Overview
      • 13.4.5 Mitsubishi Tanabe Pharma Latest Developments
    • 13.5 Pfizer
      • 13.5.1 Pfizer Company Information
      • 13.5.2 Pfizer Bacterial Vaccines for Humans Product Portfolios and Specifications
      • 13.5.3 Pfizer Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
      • 13.5.4 Pfizer Main Business Overview
      • 13.5.5 Pfizer Latest Developments
    • 13.6 Bayer
      • 13.6.1 Bayer Company Information
      • 13.6.2 Bayer Bacterial Vaccines for Humans Product Portfolios and Specifications
      • 13.6.3 Bayer Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
      • 13.6.4 Bayer Main Business Overview
      • 13.6.5 Bayer Latest Developments
    • 13.7 Emergent BioSolutions
      • 13.7.1 Emergent BioSolutions Company Information
      • 13.7.2 Emergent BioSolutions Bacterial Vaccines for Humans Product Portfolios and Specifications
      • 13.7.3 Emergent BioSolutions Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
      • 13.7.4 Emergent BioSolutions Main Business Overview
      • 13.7.5 Emergent BioSolutions Latest Developments
    • 13.8 Walvax
      • 13.8.1 Walvax Company Information
      • 13.8.2 Walvax Bacterial Vaccines for Humans Product Portfolios and Specifications
      • 13.8.3 Walvax Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
      • 13.8.4 Walvax Main Business Overview
      • 13.8.5 Walvax Latest Developments
    • 13.9 Chengdu Kanghua Biological Products Co., Ltd.
      • 13.9.1 Chengdu Kanghua Biological Products Co., Ltd. Company Information
      • 13.9.2 Chengdu Kanghua Biological Products Co., Ltd. Bacterial Vaccines for Humans Product Portfolios and Specifications
      • 13.9.3 Chengdu Kanghua Biological Products Co., Ltd. Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
      • 13.9.4 Chengdu Kanghua Biological Products Co., Ltd. Main Business Overview
      • 13.9.5 Chengdu Kanghua Biological Products Co., Ltd. Latest Developments
    • 13.10 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd.
      • 13.10.1 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Company Information
      • 13.10.2 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Bacterial Vaccines for Humans Product Portfolios and Specifications
      • 13.10.3 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
      • 13.10.4 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Main Business Overview
      • 13.10.5 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Latest Developments
    • 13.11 Zhejiang Tianyuan Biopharmaceutical Co., Ltd.
      • 13.11.1 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Company Information
      • 13.11.2 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Bacterial Vaccines for Humans Product Portfolios and Specifications
      • 13.11.3 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
      • 13.11.4 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Main Business Overview
      • 13.11.5 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Latest Developments
    • 13.12 Beijing Institute of Biological Products Co., Ltd.
      • 13.12.1 Beijing Institute of Biological Products Co., Ltd. Company Information
      • 13.12.2 Beijing Institute of Biological Products Co., Ltd. Bacterial Vaccines for Humans Product Portfolios and Specifications
      • 13.12.3 Beijing Institute of Biological Products Co., Ltd. Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
      • 13.12.4 Beijing Institute of Biological Products Co., Ltd. Main Business Overview
      • 13.12.5 Beijing Institute of Biological Products Co., Ltd. Latest Developments
    • 13.13 CanSino Biological Co., Ltd.
      • 13.13.1 CanSino Biological Co., Ltd. Company Information
      • 13.13.2 CanSino Biological Co., Ltd. Bacterial Vaccines for Humans Product Portfolios and Specifications
      • 13.13.3 CanSino Biological Co., Ltd. Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
      • 13.13.4 CanSino Biological Co., Ltd. Main Business Overview
      • 13.13.5 CanSino Biological Co., Ltd. Latest Developments
    • 13.14 Hualan Biological Vaccine Co., Ltd.
      • 13.14.1 Hualan Biological Vaccine Co., Ltd. Company Information
      • 13.14.2 Hualan Biological Vaccine Co., Ltd. Bacterial Vaccines for Humans Product Portfolios and Specifications
      • 13.14.3 Hualan Biological Vaccine Co., Ltd. Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
      • 13.14.4 Hualan Biological Vaccine Co., Ltd. Main Business Overview
      • 13.14.5 Hualan Biological Vaccine Co., Ltd. Latest Developments
    • 13.15 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd.
      • 13.15.1 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Company Information
      • 13.15.2 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Bacterial Vaccines for Humans Product Portfolios and Specifications
      • 13.15.3 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
      • 13.15.4 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Main Business Overview
      • 13.15.5 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Latest Developments
  • 14 Research Findings and Conclusion

USD 3,660 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.